Clostridium tetani toxoid antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Clostridium tetani toxoid antigen (formaldehyde inactivated)
Accession Number
DB10583
Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated / Toxoid
Description

Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium sulfate filtration and precipation.

Synonyms
  • Tetanus toxoid
  • Tetanus toxoid adsorbed
  • tetanus toxoid vaccine, inactivated
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tetanus Toxoid AdsorbedInjection, suspension5 [Lf]/0.5mLIntramuscularSanofi Pasteur Limited2005-09-23Not applicableUs
Tetanus Toxoid AdsorbedSuspension5 lfIntramuscularId Biomedical Corporation, Quebec1991-12-312005-08-03Canada
Tetanus Toxoid AdsorbedInjection, suspension5 [Lf]/0.5mLIntramuscularSanofi Pasteur Limited2005-09-23Not applicableUs
Tetanus Toxoid Adsorbed InjLiquid5 lfIntramuscularAventis Pasteur Limited1980-12-312006-07-17Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Adacel TDaPClostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (2.5 ug/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 [Lf]/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Limited2005-06-10Not applicableUs
Adacel TDaP TDaPClostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (2.5 ug/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 [Lf]/0.5mL)Injection, suspensionIntramuscularRemedy Repack2015-11-142016-03-29Us
BoostrixClostridium tetani toxoid antigen (formaldehyde inactivated) (5 [iU]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (8 ug/0.5mL) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) (2.5 ug/0.5mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (8 ug/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2.5 [iU]/0.5mL)SuspensionIntramuscularA-S Medication Solutions2009-07-24Not applicableUs
BoostrixClostridium tetani toxoid antigen (formaldehyde inactivated) (5 [iU]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (8 ug/0.5mL) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) (2.5 ug/0.5mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (8 ug/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2.5 [iU]/0.5mL)SuspensionIntramuscularA-S Medication Solutions2009-07-24Not applicableUs
BoostrixClostridium tetani toxoid antigen (formaldehyde inactivated) (5 [iU]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (8 ug/0.5mL) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) (2.5 ug/0.5mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (8 ug/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2.5 [iU]/0.5mL)SuspensionIntramuscularGlaxoSmithKline Biologicals SA2009-07-24Not applicableUs
CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED), CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS TOXOID ANTIGEN (GLUTARALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS PERTACTIN ANTIGEN, and BORDETELLA PERTUSSIS FIMBRIAE 2/3 ANTIGENClostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (2.5 ug/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 [Lf]/0.5mL)Injection, suspensionIntramuscularA-S Medication Solutions2005-06-10Not applicableUs
D2t5 Diphtheria and Tetanus Toxoid AdsorbedClostridium tetani toxoid antigen (formaldehyde inactivated) (5 lf) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 lf)SuspensionIntramuscularIaf Biovac Inc.1998-06-291999-01-08Canada
DaptacelClostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (10 ug/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (15 [Lf]/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Limited2002-05-14Not applicableUs
DecavacClostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 [Lf]/0.5mL)SuspensionIntramuscularSanofi Pasteur Limited2004-03-242016-05-19Us
Diphtheria and Tetanus Toxoids AdsorbedClostridium tetani toxoid antigen (formaldehyde inactivated) (5 lf) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (25 lf)LiquidIntramuscularAventis Pasteur Limited1980-12-312001-07-19Canada
Categories
UNII
K3W1N8YP13
CAS number
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
AbituzumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Abituzumab.
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
AdalimumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.
AdecatumumabThe therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Adecatumumab.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910742
ATC Codes
J07AM52 — Tetanus toxoid, combinations with tetanus immunoglobulinJ07AM51 — Tetanus toxoid, combinations with diphtheria toxoidJ07AM01 — Tetanus toxoid
AHFS Codes
  • 80:08.00 — Toxoids

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentSubstance Use Disorder (SUD)1
1Active Not RecruitingOtherWhooping Cough1
1Active Not RecruitingTreatmentMalignant Neoplasms of Brain1
1CompletedNot AvailablePertussis1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedPreventionHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1Not Yet RecruitingPreventionInfections, Respiratory Syncytial Virus1
1RecruitingTreatmentBrain Cancer / Brain Neoplasms, Recurrent / Cancer of the Brain / Neoplasms, Brain / Primary Brain Neoplasms1
1RecruitingTreatmentGlioblastomas / Malignant Gliomas / Pediatric Brain Tumor / Pediatric Brain Tumor, Recurrent / Pediatric Glioblastoma Multiforme / Recurrent Medulloblastoma1
1TerminatedTreatmentGerm Cell Tumors / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm1
1, 2Active Not RecruitingPreventionDiphtheria / Tetanus / Whooping Cough1
2CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type B / Haemophilus Influenzae Type b Diseases / Pertussis / Poliomyelitis / Serogroup C Meningococcal Diseases / Tetanus / Viral Hepatitis B1
2CompletedPreventionHealthy Volunteers / Meningococcal Infections1
2CompletedPreventionInfections, Respiratory Syncytial Virus1
2CompletedPreventionInfections, Respiratory Syncytial Virus / Respiratory Synctial Virus Infections1
2CompletedPreventionInfections, Rotavirus / Rotavirus Gastroenteritis1
2CompletedPreventionMeningitis / Meningococcal Infections / Meningococcal Meningitis1
2CompletedPreventionMeningococcal Infections1
2CompletedPreventionShigella Sonnei Infection1
2CompletedTreatmentRelapsing Forms of Multiple Sclerosis1
2Not Yet RecruitingPreventionClostridium Difficile Immunisation / Diphtheria / Diphtheria Immunisation / Pertussis / Tetanus / Tetanus Immunisation1
2RecruitingBasic ScienceAstrocytomas / Gliomas / Oligodendrogliomas1
2RecruitingPreventionPertussis / Whooping Cough1
2SuspendedTreatmentPlasma Cell Myeloma1
2Unknown StatusTreatmentColorectal Cancers1
3CompletedPreventionAcellular Pertussis / Diphtheria / Diphtheria, Tetanus, Pertussis, Poliomyelitis / Tetanus1
3CompletedPreventionAcellular Pertussis / Diphtheria / Diphtheria-Tetanus-acellular Pertussis Vaccines / Pertussis / Tetanus1
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Viral Hepatitis B1
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type B / Tetanus1
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type b Diseases / Pertussis / Tetanus2
3CompletedPreventionAcellular Pertussis / Diphtheria / Pertussis / Poliomyelitis / Tetanus1
3CompletedPreventionAcellular Pertussis / Diphtheria / Pertussis / Tetanus2
3CompletedPreventionAcellular Pertussis / Diphtheria / Poliomyelitis / Tetanus / Viral Hepatitis B1
3CompletedPreventionAcellular Pertussis / Diphtheria / Tetanus3
3CompletedPreventionAcute Otitis Media / Infections, Pneumococcal / Secretory Otitis Media / Tympanic Membrane Perforation1
3CompletedPreventionBacterial Infections / Neisseria Meningitidis / Virus Diseases3
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type B / Pertussis / Poliomyelitis / Tetanus1
3CompletedPreventionHaemophilus Influenzae Type B1
3CompletedPreventionHaemophilus Influenzae Type B / Haemophilus Influenzae Type b Diseases / Meningococcal Serogroup C Diseases / Neisseria Meningitidis1
3CompletedPreventionHepatitis A / Hepatitis A Vaccine1
3CompletedPreventionHerpes Zoster1
3CompletedPreventionInfections, Rotavirus1
3CompletedPreventionInfections, Rotavirus / Meningococcal Meningitis1
3CompletedPreventionInvasive Disease Caused by Neisseria Meningitidis Due to Serogroups A, C, W-135, Y / Meningococcal Infections1
3CompletedPreventionInvasive Pneumococcal Disease (IPD) / Neisseria Meningitidis (Bacterial Meningitis)1
3CompletedPreventionMeningitis / Meningococcal Meningitis1
3CompletedPreventionMeningococcal Disease / Meningococcal Infections1
3CompletedPreventionMeningococcal Infections3
3CompletedPreventionMeningococcal Infections / Meningococcal Serogroup A, C, W-135, Y Diseases1
3CompletedPreventionMeningococcal Meningitis1
3CompletedPreventionNeisseria Meningitidis1
3CompletedPreventionPapillomavirus Infections1
3CompletedPreventionPoliomyelitis1
3CompletedPreventionVaccines, Pneumococcal1
3Not Yet RecruitingPreventionMeningococcal Infections1
4Active Not RecruitingBasic SciencePrevention of Infections With Bordetella Pertussis1
4CompletedPreventionAcellular Pertussis / Diphtheria / Tetanus2
4CompletedPreventionAcellular Pertussis / Diphtheria / Tetanus / Tetanus and Pertussis1
4CompletedPreventionDiphtheria, Tetanus and Pertussis / Haemophilus Influenzae Serotype b Disease / Meningococcal Disease / Pneumococcal Diseases / Viral Hepatitis B1
4CompletedPreventionDiphtheria-Tetanus-acellular Pertussis Vaccines1
4CompletedPreventionDiphtheria / Meningococcal / Pertussis Diseases / Streptococcal / Tetanus1
4CompletedPreventionDiphtheria / Pertussis / Tetanus2
4CompletedPreventionDiphtheria / Pertussis / Tetanus / Whooping Cough2
4CompletedPreventionDiphtheria / Tetanus1
4CompletedPreventionHepatitis A Virus1
4CompletedTreatmentImmunizations / Meningitis / Pertussis / Preventive Immunization; Meningitis1
4RecruitingPreventionMeningococcal Disease, Invasive1
4RecruitingPreventionPertussis1
4RecruitingTreatmentSnake Bites1
4TerminatedPreventionAcellular Pertussis / Diphtheria / Hepatitis A / Pertussis / Tetanus1
Not AvailableCompletedNot AvailableAcellular Pertussis / Diphtheria / Tetanus3
Not AvailableCompletedNot AvailableViral Hepatitis B1
Not AvailableCompletedPreventionProlonged Apnea / Prolonged Bradycardia1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableTerminatedNot AvailableCancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, suspensionIntramuscular
LiquidIntramuscular
Kit; powder, for solutionIntramuscular
Kit
SuspensionIntramuscular
Injection, suspensionIntramuscular5 [Lf]/0.5mL
SuspensionIntramuscular5 lf
LiquidIntramuscular5 lf
InjectionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:04 / Updated on October 16, 2018 08:42